Astellas sees US Xtandi sales reaching $400m this fiscal year
This article was originally published in Scrip
Astellas has cut its guidance for both sales and profit for the fiscal year ending 31 March, despite a strong start in the US for its prostate cancer drug Xtandi (enzalutamide; licensed from Medivation).
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.